Endothelin-1 (ET-1) is elevated in patients with atrial fibrillation (AF) and heart failure. We investigated effects of ET-1 on human atrial cellular electrophysiological measurements expected to influence the genesis independently of β-blocker treatment, may be expected to contribute a potentially anti-arrhythmic influence in the atria of patients with AF and heart failure.
Introduction.
Endothelin-1 exerts a wide variety of cardiovascular effects [1] [2] [3] . The consequences of these on the cardiac rhythm are currently under investigation. They may be influenced by the concentration of ET-1, the species and cardiac chamber studied, the presence of adrenergic stimulation and the degree of any coronary vasoconstriction by ET-1 [1, 3] . Endothelin-1 provoked arrhythmias in the ventricles, by prolonging action potentials and promoting afterdepolarisations, particularly in dogs in-vivo [4] [5] [6] . The effects of ET-1 on atrial arrhythmias, such as atrial fibrillation (AF), however, are less clear. Recent reports have highlighted potentially pro-arrhythmic effects on intracellular Ca 2+ ((Ca 2+ ) i ) handling, via activation of inositol-1,4,5 trisphosphate (IP 3 ) receptors [7] [8] [9] [10] . Endothelin-1 also produced arrhythmic contractions in human atria [11] .
However, to our knowledge, the effects of ET-1 on human atrial electrophysiological activity likely to influence the genesis and/or maintenance of AF have not been studied.
Endothelin-1 has consistently been reported to exert a marked anti-adrenergic reduction in L-type Ca 2+ current (I CaL ) in both the atria and ventricles [12] [13] [14] [15] . This effect is invariably and substantially larger than any change by ET-1 in basal (non-adrenergically-stimulated) I CaL [12] [13] [14] [15] , including in human atria [13, 14] .
The I CaL is a major determinant of action potential morphology, including in human atrial cells [16] . This current also may play a role in the development of abnormal automaticity and afterdepolarisations, both early (EAD) and delayed (DAD) [17] . Plasma ET-1 elevation is independently associated with AF in patients with congestive heart failure (CHF) [18, 19] . Since catecholamines also are elevated in CHF [20] , it is conceivable that such anti-adrenergic reduction in atrial I CaL by ET-1 might attenuate AF genesis, by inhibiting abnormal automaticity, EADs or DADs. However, it might also promote re-entrant AF, by shortening the action potential and effective refractory period (ERP). The effects of ET-1 on either action potentials or these arrhythmogenic electrophysiological mechanisms have not been studied in human atrial cells.
Beta-adrenoceptor antagonists (β-blockers) are increasingly used to treat patients with AF and CHF.
These drugs may oppose pro-arrhythmic influences of elevated sympathetic drive. They may also potentiate atrial arrhythmic contractions induced by ET-1 and catecholamines [11, 21] . We have demonstrated that long term treatment of patients with a β-blocker was associated with prolongation of late repolarisation and the ERP, in atrial isolated myocytes [22] . However, the influences of such treatment on atrial cellular electrophysiological responses to ET-1 are unknown.
The aim of this study, therefore, was two-fold. Firstly, to investigate effects of ET-1 and the sympathomimetic isoproterenol (ISO), alone and in combination, on human atrial cellular action potential 4/25 morphology, ERP, arrhythmogenic electrophysiological activity and I CaL . Secondly, to compare these effects between groups of patients treated and not treated chronically with a β-blocker.
Materials and Methods.
Right atrial appendage tissue (weight: 0.39±0.03 g) was obtained from 66 consenting patients in sinus rhythm undergoing cardiac surgery. Procedures were approved by the institutional research ethics committee. Atrial cells were isolated by enzymatic dissociation and mechanical disaggregation, using protease (Type XXIV, 4 U/ml, Sigma) and collagenase (Type 1, 330 U/ml, Worthington), as described previously [16, 22] .
Action potentials and I CaL were recorded using the whole-cell patch clamp technique, in perforatedpatch configuration to limit intracellular dialysis. Glass microelectrodes were pulled and heat-polished to 
Endothelin-receptor involvement in L-type Ca 2+ current response to ET-1.
The ET A antagonist FR139317 (10 nM) partially reversed the anti-adrenergic effect of 10 nM ET-1 on I CaL . Figure 2A shows that FR139317 produced a gradual increase in I CaL after the characteristic ET-1 response, in the continued presence of ISO and ET-1. FR139317 exerted a similar effect in each of 6 cells (4 patients),
with a significant reversal of the anti-adrenergic effect of ET-1 by 22±7% (P<0.05). Figure 2B shows that FR139317 had no effect on ISO-stimulated I CaL , and when co-applied prior to ET-1, prevented the antiadrenergic effect of ET-1. The ET B agonist sarafotoxin (S6c) at 10 nM had no effect on basal (non-ISOstimulated) I CaL ( Figure 2C ). I CaL in the absence and presence of S6c was -3.9±1.1 and -3.3±0.8 pA/pF, respectively (P>0.05, n=5 cells, 3 patients). Following S6c washout, ISO stimulated an increase in I CaL which was unaffected by the re-addition of S6c, but which was reversed by ET-1 in the continued presence of S6c
( Figure 2C ).
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Effects of ISO and ET-1 on action potentials and effective refractory period.
Isoproterenol at 0.05 µM elevated the action potential plateau, as shown by the original recordings in Figure   3A (upper panel). This was associated with a marked prolongation of early and mid repolarisation, but later repolarisation was unaffected ( Figure 3A , upper panel Figure 3A , upper panel, with confirmatory mean data from 10 patients given in the lower panel. Figure 3B (upper panel) shows that 0.05 µM ISO had no effect on either action potential restitution or the cellular ERP, in line with its lack of effect on APD 90 . These measurements also were unaffected by the combination of 0.05 µM ISO and 10 nM ET-1. The absence of changes in ERP were confirmed by mean data in Figure 3B (lower panel). Figure 4A shows that ET-1 (10 nM) had no significant effect on action potential shape or mean APD 50 in the absence of ISO. Endothelin-1 (10 nM) also had no significant effect, in the absence of 
Cellular arrhythmic depolarisations induced by ISO, and anti-adrenergic effect of ET-1.
Action potentials recorded using a repetitive stimulation protocol in the presence of ISO (0.05 µM) were frequently interrupted by low amplitude, usually sub-threshold, transient depolarisations. We have termed these "cellular arrhythmic depolarisations" (CADs). typical response to ET-1 in the absence of ISO, i.e. lack of production of CADs. Figure 5B shows that ISO produced CADs in a significant number of cells (panel i) and that, in cells in which ISO and ET-1 were coapplied, ET-1 abolished ISO-induced CADs (panel ii). By contrast, ET-1 alone had no significant effect on the incidence of CADs (panel iii).
Effects of β β β β-blocker therapy on basal electrophysiology and responses to ISO and ET-1.
The atrial cell basal ERP, i.e. in the absence of ISO, was significantly longer in a group of patients treated with a β-blocker for ≥7 days pre-operatively (221±9 ms; 50 cells, 13 patients), than in a group of non-β-blocked patients (184±15 ms; 22 cells, 7 patients; P<0.05). However, there were no significant differences between these patient groups in the basal electrophysiological measurements which were shown subsequently to be affected by either ISO or ET-1. The basal peak I CaL density and the basal I CaL voltagedependency were similar in the two patient groups ( Figure 6 , panels A and B). The basal APD 50 also was not significantly affected (panel C). Furthermore, the magnitude of neither of the observed significant effects of 0.05 µM ISO, i.e. to increase peak I CaL and APD 50 , was significantly different between these patient groups (panels D and E, respectively). Finally, there was no significant difference between β-blocked and non-β-blocked patient groups in the subsequent ET-1 (10 nM)-induced reduction in APD 50 (panel F).
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Discussion.
The effects of ET-1 on action potentials were studied for the first time to our knowledge in human atrium.
Endothelin-1 exerted a marked anti-adrenergic action, abolishing the prolongation of APD produced by ISO.
By contrast, ET-1 had no significant basal action, i.e. in the absence of adrenergic stimulation. The effects of ET-1 on action potentials have been studied only rarely in the atrium of any species [23] [24] [25] . Anti-adrenergic effects have not been investigated and the basal responses are equivocal [23] [24] [25] . Endothelin-1 raised the plateau of "slow response action potentials" in guinea-pig atrium [23] . It also shortened the APD in guineapig [24] and canine [25] atria. In the ventricle, by contrast, numerous studies, particularly canine have demonstrated an APD prolonging action of ET-1 [4] [5] [6] 26] .
In the present study, ET-1 abolished atrial cellular arrhythmic depolarisations (CADs) provoked by ISO during action potential trains. We studied single cells, so this can be considered to be a direct electrophysiological effect of ET-1, not secondary to, for example, coronary vasoconstriction. Endothelin-1 did not produce significant numbers of CADs in the absence of adrenergic stimulation, even at a 10 3 -fold higher concentration than was anti-adrenergic on I CaL . By contrast, ET-1 induced arrhythmic contractions in human atrial tissues [9, 11] . Atrial contraction was not measured in the present study, and ET-1 exerts various contractile effects not requiring electrophysiological changes [1, 2] . These may include enhanced Ca 2+ -induced Ca 2+ release (CICR) by IP 3 activation, phosphorylation of myosin light chains, and enhancement of myofilament Ca 2+ responsiveness. Some may account, at least in part, for the apparent discrepancy between the effect of ET-1 to induce arrhythmic contractions but not to produce CADs. Methodological differences between studies may contribute also, e.g. with blockade of β 1 and β 2 adrenoceptors in both contraction studies [9, 11] . Furthermore, arrhythmic contractions induced by ET-1 are not mediated by ET A receptors [11] . Since effects of ET-1 on I CaL were mediated by ET A , in the present and other studies [13, 14] , the arrhythmic contractions may be largely independent of I CaL . In support, effects of ET-1 on atrial contractility were shown to not require an involvement of I CaL , even though its involvement could also be demonstrated [27] . Endothelin-1 elevated (Ca 2+ ) i concentration, Ca 2+ transient amplitude and spark frequency in rat, cat and mouse atria, via IP 3 activation [7, 8, 10] . It also induced diastolic premature Ca 2+ transients [7] and facilitated arrhythmogenic Ca 2+ waves [8] . In one of these studies [7] , premature Ca 2+ transients were accompanied by action potentials. These effects of ET-1 on (Ca 2+ ) i could exert an arrhythmogenic influence in the atria of patients. Such extrapolation should be made with caution, however. The atrial studies [7, 8, 10] were not on human tissues, and the lowest concentration of ET-1 used in each (100 nM) was ~10 4 -fold 10/25 greater than the highest levels reported in patients (6-12 pM) [20, 28] . In the studies showing pro-arrhythmic effects of ET-1 on contractility [9, 11] and (Ca 2+ ) i handling [7, 8, 10] , the atrial tissues were not under adrenergic stimulation. However, ET-1 produced marked negative inotropism in human atrium in the presence of catecholamines [29] . Therefore, ET-1 exerts marked anti-adrenergic effects on atrial contractility, as well as on CADs.
The CADs produced by catecholamine in this study occurred in cells with a relatively marked prolongation of the APD. This is consistent with the reported association between APD lengthening and the development of afterdepolarisations [17] . Many of these CADs displayed characteristics of abnormal automaticity, and possibly EADs or DADs. Their suppression by ET-1 could, therefore, contribute an inhibitory influence on non re-entrant mechanisms of AF. Consistent with that, intracoronary ET-1 prevented AF produced by intravenous ISO in dogs [5] . Furthermore, ET-1 lacked effect on either the cellular ERP or the action potential V max . This suggests that ET-1 may not alter the minimum path length for re-entry, and therefore not promote (or inhibit) re-entrant AF. The anti-adrenergic effects of ET-1 were observed at extremely low, clinically relevant concentrations (down to 10 pM), despite near-maximal adrenergic stimulation. They might be expected to occur also, therefore, in patients with CHF whose catecholamine levels are elevated [20] . Nevertheless, extrapolation should be made with caution, since it is presently unknown whether such effects of ET-1 would be preserved in patients with AF or CHF. Of note, the modulation of I CaL by PKC, which is involved in ET-1 signalling [30, 31] , was impaired in chronic AF [32] . It is also unclear whether AF causes ET-1 elevation in the absence of CHF or other myocardial diseases [33] .
Furthermore, the chronic effects of ET-1, rather than the relatively acute effects studied here and elsewhere, are presently unknown. These could include, for example, a long term adaptive response akin to "pharmacological remodelling" [22] .
Afterdepolarisations are affected by changes in I CaL [17] . In the present study, this current was reduced markedly by ET-1 when adrenergically stimulated, whilst non-adrenergically stimulated I CaL was unaffected.
We limited cytosolic dialysis, and thus efflux of intracellular messengers required for ET-1 signalling, by using the perforated patch configuration. In a study using ruptured patch, ET-1 reduced basal I CaL in human atrium [13] . However, in line with the present data, it had no effect on basal I CaL when intracellular GTP was present [13] . In another study, ET-1 either increased or decreased human atrial basal I CaL , depending on the pre-ET-1 I CaL density, again using ruptured patch [14] . In the atria of other species, either an absence of effect of ET-1 on basal I CaL [12, 34] or a decrease [24] have been demonstrated. However, no reports of I CaL
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increase by ET-1 were found in atrium. The effects of ET-1 on basal I CaL in the ventricles have been studied more widely. These include a decrease [26, 35] , no change [15, 36] or an increase [37, 38] . In each of these atrial and ventricular studies in which basal and anti-adrenergic effects of ET-1 were compared [12] [13] [14] [15] 34, 36, 37] , the most consistent and predominant effect was an anti-adrenergic reduction in I CaL . This has been shown to involve cAMP and G i protein in human atrial cells [14] . The present conformity of effects of ISO, ET-1 and their combination on I CaL , APD and CADs suggests that CAD abolition by ET-1 involved the anti-adrenergic reduction in I CaL . Consistent with this, an I CaL agonist produced APD lengthening and EADs in canine myocardial bundle branch, and each effect was abolished by an I CaL blocker [4] . The reduction in I CaL by ET-1 also may involve (Ca 2+ ) i -induced inactivation of this current, via enhanced CICR [9, 10] .
Furthermore, a Cl -current activated by ISO and cAMP was inhibited by ET-1 in human atrial cells [39] .
However, this current was present in ~20% of cells and required 30 nM ET-1 to affect. Endothelin-1 increased the human atrial Na + current (I Na ) [13] . This was measured using low extracellular Na
However, we and others [6, 26] found no significant effect of ET-1 on action potential V max , a reliable indicator of I Na , at physiological [Na + ] o and temperature. Nevertheless, effects of ET-1, either basal or anti-adrenergic, on currents additional to I CaL cannot be excluded.
Chronic treatment of patients with a β-blocker was associated with a prolonged atrial cellular ERP, in the absence of adrenergic stimulation. This is considered to be a component of "pharmacological remodelling", since the β-blocker is presumed to be removed by the repeated washing of cells during their isolation [22] . The basal APD 50 and I CaL were unchanged by chronic β-blockade, also consistent with the earlier study [22] . In the present study, chronic β-blockade did not influence the effects of ISO or the antiadrenergic effects of ET-1 on these measurements. Such patient treatment has been associated with potentiation of atrial arrhythmic contractions by β 2 -adrenoceptor stimulation [21] and by ET-1 [11] , though anti-adrenergic actions of ET-1 were not investigated [11] . The present data are in line with a reported lack of influence of chronic β-blockade on human atrial I CaL responses to ET-1 [14] . The concentrations of ISO and ET-1 we used indicate that the E max of the electrophysiological responses was unaffected by chronic β-blockade. However, the possibility that the potency of these responses may be affected, cannot be excluded.
The present data suggest that ET-1 may contribute a potentially anti-arrhythmic electrophysiological influence in human atrium in the presence of adrenergic stimulation. This influence may not be affected by the treatment of patients with β-blockers. It should be considered alongside the potentially pro-arrhythmic 12/25
influences of ET-1 on (Ca 2+ ) i handling and myocardial contractility in the absence of adrenergic stimulation.
Elevation of ET-1 is an adverse prognostic marker in CHF [40] . However, ET-receptor antagonists do not reduce mortality, despite their short term haemodynamic benefit, in patients with CHF [41] . It is conceivable that potentially beneficial electrophysiological influences of ET-1 might be blunted by the blockade of cardiac ET-receptors. Values are means±SE. NS=not significant. Group sizes (c=cells, p=patients): A, +BB: 114c, 34p, -BB: 52c, 13p; B, +BB: 62c, 21p, -BB: 22c, 7p; C, +BB: 55c, 13p, -BB: 23c, 7p; D, +BB: 61c, 25p, -BB: 18c, 9p; E, +BB, -BB: 11c, 6p each; F, +BB: 7c, 5p, -BB: 8c, 5p. 
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